Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy.

Saved in:
Bibliographic Details
Title: Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy.
Authors: Yeboa DN; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. dnyeboa@mdanderson.org.; 1515 Holcombe Blvd, Unit 97, Houston, TX, 77030, USA. dnyeboa@mdanderson.org., Whitfield BT; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lin R; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ejezie CL; Department of Health Sciences, Towson University, Towson, MD, USA., Swanson TA; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Beckham TH; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang C; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., De B; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Perni S; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tom MC; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li J; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., McGovern SL; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Harrison R; Division of Neurology, University of British Columbia, Vancouver, Canada., Majd NK; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Puduvalli VK; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Aaroe AE; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghin M; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., O'Brien BJ; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel AD; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel CB; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wefel JS; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Taslicay CA; Quantitative Imaging Analysis Core, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gule-Monroe M; Department of Neuroradiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Paulino AC; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., McAleer MF; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grosshans DR; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ghia AJ; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jiang W; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chung C; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maor M; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang CH; Department of Biostatistics, Yale University, New Haven, CT, USA., Gubbiotti MA; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kamiya-Matsuoka C; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ballester LY; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Weathers SP; Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huse JT; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: Journal of neuro-oncology [J Neurooncol] 2025 Nov 05; Vol. 176 (1), pp. 72. Date of Electronic Publication: 2025 Nov 05.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1573-7373
DOI:10.1007/s11060-025-05269-6